Related references
Note: Only part of the references are listed.New treatment modalities in advanced thyroid cancer
E. Kapiteijn et al.
ANNALS OF ONCOLOGY (2012)
Molecular target based combinational therapeutic approaches in thyroid cancer
Shilpi Rajoria et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Management of refractory thyroid cancers
M. Schlumberger
ANNALES D ENDOCRINOLOGIE (2011)
The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204)
Joanna Xing et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
Merina Ahmed et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Keith C. Bible et al.
LANCET ONCOLOGY (2010)
Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib
Bruno Vincenzi et al.
ONCOLOGIST (2010)
Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets
Jeffrey A. Knauf et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
Hendrieke Hoftijzer et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
Richard T. Kloos et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase
Junji Matsui et al.
CLINICAL CANCER RESEARCH (2008)
Phase II trial of sorafenib in advanced thyroid cancer
Vandana Gupta-Abramson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
Junji Matsui et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
The prevalence and prognostic value of BRAF mutation in thyroid cancer
Electron Kebebew et al.
ANNALS OF SURGERY (2007)
Targeting BRAF in thyroid cancer
A. V. Espinosa et al.
BRITISH JOURNAL OF CANCER (2007)
The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane
G Riesco-Eizaguirre et al.
ENDOCRINE-RELATED CANCER (2006)
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer
BR Smith et al.
THYROID (2006)
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
Furio Pacini et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Molecular pathogenesis of thyroid cancer
DL Segev et al.
SURGICAL ONCOLOGY-OXFORD (2003)
Share Paper
